Przejdź do zawartości
Merck
Wszystkie zdjęcia(2)

Dokumenty

HCVD1MAG-67K

Millipore

MILLIPLEX® Human Cardiovascular Disease (CVD) Magnetic Bead Panel 1 - Cardiovascular Disease Multiplex Assay

The analytes available for this multiplex kit are: BNP, NT-proBNP, CK-MB, CXCL6/GCP-2, CXCL16, Endocan-1 (ESM-1), FABP3, FABP4, LIGHT, Oncostatin (OSM), Placental Growth Factor (PlGF), Troponin I (TnI).

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(2)

About This Item

Kod UNSPSC:
12161503
eCl@ss:
32161000
NACRES:
NA.84

Poziom jakości

200

reaktywność gatunkowa

human

producent / nazwa handlowa

Milliplex®

assay range

accuracy: 100%
(CK-MB)
accuracy: 102%
(LIGHT)
accuracy: 102%
(Oncostatin (OSM))
accuracy: 103%
(CXCL6/GCP-2)
accuracy: 96%
(FABP3)
accuracy: 96%
(Placental Growth Factor (PlGF))
accuracy: 97%
(NT proBNP)
standard curve range: 137.2-100,000 pg/mL
(FABP3)
standard curve range: 2.7-2,000 pg/mL
(Placental Growth Factor (PlGF))
standard curve range: 34.3-25,000 pg/mL
(NT proBNP, CXCL16, Endocan-1 (ESM-1), LIGHT)
standard curve range: 6.9-5,000 pg/mL
(CXCL6, Oncostatin (OSM))
standard curve range: 68.6-50,000 pg/mL
(BNP, CK-MB, Troponin I (TnI))
standard curve range: 685.9-500,000 pg/mL
(FABP4)
inter-assay cv: <20%
intra-assay cv: <10%

metody

multiplexing: suitable

metoda wykrywania

fluorometric (Luminex xMAP)

Warunki transportu

wet ice

Powiązane kategorie

Opis ogólny

Cardiovascular disease, particularly atherosclerotic vascular disease, is a leading cause of global mortality, accounting for 30% of all global deaths (WHO, 2010). Inflammatory mechanisms play a vital role in the initiation, maintenance, and progression of vascular disease with a strong correlation between inflammatory markers and prognosis in acute and chronic coronary artery disease. Numerous studies have demonstrated an association of obesity and diabetes with cardiovascular risk factors.

The MILLIPLEX® Human Cardiovascular Disease (CVD) Panel 1 is a 12-plex kit to be used for the simultaneous quantification of any or all of the following analytes in human serum, plasma, or tissue/cell lysate and culture supernatant samples: BNP, NTproBNP, CK-MB, CXCL6, CXCL16, Endocan-1 (ESM-1), FABP3, FABP4, LIGHT, Oncostatin-M (OSM), Placental Growth Factor (PlGF), and Troponin I. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Cardiovascular

Specyficzność

Cross Reactivty
There was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes in this panel.

Zastosowanie

  • Analytes: BNP, CK-MB, CXCL6/GCP-2, CXCL16, Endocan-1 (ESM-1), FABP3, FABP4, LIGHT, NT-proBNP, Oncostatin M (OSM), Placental Growth Factor (PlGF), Troponin I (TnI)
  • Recommended Sample Type: Human serum, plasma, or tissue/cell culture supernatants and lysates
  • Recommended Sample Dilution: 25 μL per well of undiluted serum or plasma; tissue/cell culture samples may require dilution in appropriate control medium
  • Assay Run Time: Overnight (16-18 hours) at 2-8°C
  • Research Category: Cardiovascular Disease
  • Research Subcategory: Metabolic Disorders

Cechy i korzyści

Design your multiplex kit by choosing available analytes within this panel.

Inne uwagi

Please contact Technical Service for linearity of dilution.
Sensitivity: See kit protocol for individual analytes sensitive’s.

Informacje prawne

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Oświadczenie o zrzeczeniu się odpowiedzialności

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
This page may contain text that has been machine translated.

Hasło ostrzegawcze

Danger

Zwroty wskazujące rodzaj zagrożenia

H302 + H312 + H332,H317,H318,H373,H411

Klasyfikacja zagrożeń

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Organy docelowe

Respiratory Tract

Kod klasy składowania

10 - Combustible liquids

Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Andrew J Swift et al.
Thorax, 76(10), 1032-1035 (2021-02-27)
End points that are repeatable and sensitive to change are important in pulmonary arterial hypertension (PAH) for clinical practice and trials of new therapies. In 42 patients with PAH, test-retest repeatability was assessed using the intraclass correlation coefficient and treatment
Luca Di Antonio et al.
Scientific reports, 8(1), 15631-15631 (2018-10-26)
The aim of the study was to assess retinal vascular changes using optical coherence tomography angiography (OCTA) and aqueous humour changes of vascular endothelial growth factor (VEGF) and placental growth factor (PIGF) levels in treatment-naïve myopic choroidal neovascularization (mCNV) after
Li-Rong Yu et al.
Experimental biology and medicine (Maywood, N.J.), 243(3), 248-255 (2017-12-12)
Cancer treatment with doxorubicin (DOX) can induce cumulative dose-dependent cardiotoxicity. Currently, there are no specific biomarkers that can identify patients at risk during the initial doses of chemotherapy. The aim of this study was to examine plasma cytokines/chemokines and potential
Kévin Contrepois et al.
Cell, 181(5), 1112-1130 (2020-05-30)
Acute physical activity leads to several changes in metabolic, cardiovascular, and immune pathways. Although studies have examined selected changes in these pathways, the system-wide molecular response to an acute bout of exercise has not been fully characterized. We performed longitudinal
Seungwon An et al.
The ocular surface, 17(3), 589-614 (2019-04-10)
To investigate the role of neutrophil extracellular traps (NETs) and NET-associated proteins in the pathogenesis of oGVHD and whether dismantling of NETs with heparin reduces those changes. Ocular surface washings from oGVHD patients and healthy subjects were analyzed. Isolated peripheral
Wyświetl wszystkie powiązane dokumenty

Powiązane treści

Multiplex CVD Biomarker Measurement

Multiplex CVD panels like MILLIPLEX® assays enhance biomarker discovery for cardiovascular disease research.

Wielokrotny pomiar biomarkerów CVD

Panele multipleksowe CVD, takie jak testy MILLIPLEX®, usprawniają odkrywanie biomarkerów w badaniach nad chorobami układu krążenia.

MILLIPLEX® PLEXpedition Multiplex Biomarker Screening Panel

Simplify protein biomarker discovery with the MILLIPLEX® PLEXpedition 115-Plex Multiplex Screening Panel. Effortlessly screen cytokines and other markers with Luminex® technology.

MILLIPLEX® PLEXpedition Multiplex Biomarker Screening Panel

Uprość odkrywanie biomarkerów białkowych dzięki multipleksowemu panelowi przesiewowemu MILLIPLEX® PLEXpedition 115-Plex. Bez wysiłku badaj cytokiny i inne markery dzięki technologii Luminex®.

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej